Who are AZD0486's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Everolimus Tablets, Drug: Everolimus, Everolimus (Afinitor) tablets, Everolimus (Afinitor®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azd0486.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

AZD0486 — Competitive Intelligence Brief

AZD0486 (AZD0486) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mTORC1 inhibitor. Area: Oncology.

phase 3 mTORC1 inhibitor mTORC1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD0486 (AZD0486) — AstraZeneca. AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZD0486 TARGET	AZD0486	AstraZeneca	phase 3	mTORC1 inhibitor	mTORC1
Everolimus Tablets	Everolimus Tablets	Shandong Suncadia Medicine Co., Ltd.	marketed	mTOR inhibitor	mTOR (mTORC1)
Drug: Everolimus	Drug: Everolimus	Grupo Espanol de Tumores Neuroendocrinos	phase 3	mTOR inhibitor	mTORC1
Everolimus (Afinitor) tablets	Everolimus (Afinitor) tablets	Exelixis	phase 3	mTOR inhibitor	mTOR (mTORC1)
Everolimus (Afinitor®)	Everolimus (Afinitor®)	Odense University Hospital	phase 3	mTOR inhibitor	mTOR (mTORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mTORC1 inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD0486 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd0486. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab